Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026)
Johnson & Johnson (JNJ) posted Retained Earnings of $171.7 billion for Q2 2026, up 1.48% sequentially from $169.2 billion in Q1 2026, and up 3.81% YoY from $165.4 billion in Q2 2025.
Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Retained Earnings for 18 years, with the latest figure at $171.7 billion in Q2 2026.
- Quarterly Retained Earnings rose 3.81% year-over-year to $171.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $171.7 billion (up 3.81% YoY) and the FY2025 annual result came in at $169.0 billion, up 8.46% from the prior year.
- Retained Earnings improved to $171.7 billion in Q2 2026 per JNJ's latest filing, from $169.2 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $171.7 billion in Q2 2026 and troughed at $123.1 billion in Q1 2022.
- A 5-year average of $148.2 billion and a median of $153.8 billion in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings advanced 0.14% in 2023, then increased 23.14% in 2024.
- Over 5 years, Retained Earnings stood at $127.9 billion in 2022, then climbed by 20.27% to $153.8 billion in 2023, then grew by 1.27% to $155.8 billion in 2024, then grew by 8.46% to $169.0 billion in 2025, then increased by 1.59% to $171.7 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $171.7 billion, $169.2 billion, and $169.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 171.67 Bn |
| Mar 29, 2026 | 169.16 Bn |
| Dec 28, 2025 | 168.98 Bn |
| Sep 28, 2025 | 167.28 Bn |
| Jun 29, 2025 | 165.37 Bn |
| Mar 30, 2025 | 162.64 Bn |
| Dec 29, 2024 | 155.79 Bn |
| Sep 29, 2024 | 155.18 Bn |
| Jun 30, 2024 | 155.36 Bn |
| Mar 31, 2024 | 153.38 Bn |
| Dec 31, 2023 | 153.84 Bn |
| Oct 1, 2023 | 152.54 Bn |
| Jul 2, 2023 | 129.38 Bn |
| Apr 2, 2023 | 124.56 Bn |
| Jan 1, 2023 | 128.35 Bn |
| Oct 2, 2022 | 127.92 Bn |
| Jul 3, 2022 | 126.22 Bn |
| Apr 3, 2022 | 124.38 Bn |
| Jan 2, 2022 | 123.06 Bn |
| Oct 3, 2021 | 121.09 Bn |